Neoadjuvant chemotherapy in advanced ovarian cancer: What kind of evidence is needed to convince US gynaecological oncologists?

Ignace Vergote, Frederic Amant, Karin Leunen

Other Departments

Research output: Contribution to journal › Editorial › Academic › peer-review

31 Citations (Scopus)

Original language	English
Pages (from-to)	1-2
Journal	Gynecologic Oncology
Volume	119
Issue number	1
DOIs	https://doi.org/10.1016/j.ygyno.2010.08.011
Publication status	Published - 2010

Access to Document

https://doi.org/10.1016/j.ygyno.2010.08.011

Cite this

@article{4937509ab63d4c7096bee60212cacbce,

title = "Neoadjuvant chemotherapy in advanced ovarian cancer: What kind of evidence is needed to convince US gynaecological oncologists?",

author = "Ignace Vergote and Frederic Amant and Karin Leunen",

year = "2010",

doi = "https://doi.org/10.1016/j.ygyno.2010.08.011",

language = "English",

volume = "119",

pages = "1--2",

journal = "Gynecologic Oncology",

issn = "0090-8258",

publisher = "Academic Press Inc.",

number = "1",

}

TY - JOUR

T1 - Neoadjuvant chemotherapy in advanced ovarian cancer: What kind of evidence is needed to convince US gynaecological oncologists?

AU - Vergote, Ignace

AU - Amant, Frederic

AU - Leunen, Karin

PY - 2010

Y1 - 2010

U2 - https://doi.org/10.1016/j.ygyno.2010.08.011

DO - https://doi.org/10.1016/j.ygyno.2010.08.011

M3 - Editorial

C2 - 20833283

SN - 0090-8258

VL - 119

SP - 1

EP - 2

JO - Gynecologic Oncology

JF - Gynecologic Oncology

IS - 1

ER -